Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inhaled cannabis
- Development stage
- Unknown
- Lead developer
- Tetra Bio-Pharma
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Inhaled cannabis refers to the administration of cannabis through smoking or vaporization. This method provides the fastest delivery of cannabinoids to the bloodstream, with peak blood concentration occurring within 5-10 minutes after inhalation. The primary active compounds in cannabis include THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol), which interact with the endocannabinoid system. Inhaled cannabis is often used for medical purposes to manage chronic pain, neuropathic pain, muscle spasms in multiple sclerosis, and chemotherapy-induced nausea and vomiting.
- Other names
- smoked cannabisvaporized cannabiscannabis vapor
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on inhaled cannabis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inhaled cannabis.